D-Mannitol

Phase 2Small molecule

TThiogenesis Therapeutics, Inc.

D-Mannitol is one of 3 small molecule programs targeting Leigh syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leigh SyndromeActive, not recruiting

Leigh SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Leigh Syndrome

#DrugCompanyPhaseTrials

Rapamune

PPrism Pharmaceuticals

Phase 2

1 2

EPI-743

EEdison Pharmaceuticals Inc

Phase 2

1 3

D-Mannitol

TThiogenesis Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Not yet recruiting

Leigh Syndrome

NCT06990984

Clinical

Trials by Indication[1]

Leigh syndrome1 trial

A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)

Not yet recruiting·TThiogenesis Therapeutics, Inc.·Phase 2·NCT06990984·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for D-Mannitol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D-Mannitol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D-Mannitol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Thiogenesis Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThiogenesis Therapeutics, Inc.

D-Mannitol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Leigh syndrome1 trial

References

Drug Info

Quick Facts

Related News